VKTX
Viking Therapeutics, Inc.
Price Chart
Latest Quote
$30.38
+0.09 (+0.30%)
Current Price
| Previous Close | $30.29 |
| Open | $30.69 |
| Day High | $31.59 |
| Day Low | $30.16 |
| Volume | 2,631,177 |
Stock Information
| Shares Outstanding | 116.11M |
| Cash Equivalents | $602.96M |
| Net Income | $-472.34M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $3.53B |
| EPS (TTM) | $-4.15 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $2.84B |
| Income | $-472.34M |
| Book/sh | $5.57 |
| Cash/sh | $5.19 |
| Employees | 59 |
Financial Ratios
| Quick Ratio | 5.67 |
| Current Ratio | 5.72 |
Returns & Margins
| ROA | -42.54% |
| ROE | -70.04% |
Ownership
| Insider Ownership | 2.79% |
| Institutional Ownership | 64.52% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -6.65 |
| P/B | 5.46 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $92.58 |
Technical Indicators
| SMA20 | $30.03 |
| SMA50 | $31.50 |
| SMA200 | $32.41 |
| RSI | 38.41 |
| ATR | 1.4069 |
| Shares Float | 113.28M |
| Short Float | 20.37% |
| Short Ratio | 10.03 |
| Volatility | 0.68 |
| Rel Volume | 1.72 |
Performance History
| Week | +6.19% |
| Month | +6.97% |
| Quarter | -10.44% |
| 6 Months | -14.95% |
| YTD | -14.23% |
| Year | +14.95% |
| 3 Years | +31.17% |
| 5 Years | +399.67% |
| 10 Years | +2184.21% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $30.38 | 3,394,100 |
| 2026-06-17 | $30.29 | 1,887,700 |
| 2026-06-16 | $29.65 | 1,375,700 |
| 2026-06-15 | $29.63 | 1,176,700 |
| 2026-06-12 | $28.75 | 1,175,800 |
| 2026-06-11 | $28.61 | 2,667,200 |
| 2026-06-10 | $27.75 | 2,739,100 |
| 2026-06-09 | $29.23 | 2,252,100 |
| 2026-06-08 | $29.24 | 2,096,400 |
| 2026-06-05 | $28.45 | 2,738,700 |
| 2026-06-04 | $29.78 | 1,726,000 |
| 2026-06-03 | $29.33 | 1,467,700 |
| 2026-06-02 | $29.29 | 2,761,500 |
| 2026-06-01 | $31.27 | 1,490,100 |
| 2026-05-29 | $32.74 | 1,746,000 |
| 2026-05-28 | $32.19 | 1,457,200 |
| 2026-05-27 | $31.66 | 1,751,200 |
| 2026-05-26 | $30.80 | 2,409,600 |
| 2026-05-22 | $30.89 | 1,222,200 |
| 2026-05-21 | $30.68 | 2,004,700 |
| 2026-05-20 | $29.44 | 1,641,600 |
| 2026-05-19 | $28.40 | 1,802,400 |
About Viking Therapeutics, Inc.
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRÃ), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRÃ for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
đ° Latest News
Viking Therapeutics, Inc. (VKTX) Gains As Market Dips: What You Should Know
Zacks âĸ 2026-06-17T21:50:05Z
Viking Therapeutics (VKTX) Offers Potential With VK2735 Market Opportunity
Insider Monkey âĸ 2026-06-17T15:55:32Z
Viking Therapeutics CMO Hire Puts Spotlight On Pipeline Progress And Valuation
Simply Wall St. âĸ 2026-06-12T08:17:56Z
Is Viking Therapeutics Stock Going to $100?
Motley Fool âĸ 2026-06-12T05:35:00Z
Viking Therapeutics, Inc. (VKTX) Falls More Steeply Than Broader Market: What Investors Need to Know
Zacks âĸ 2026-06-10T21:50:06Z
Why 1 Wall Street Analyst Thinks Viking Therapeutics Stock Could Soar 188%
Motley Fool âĸ 2026-06-10T17:47:00Z
Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider
Zacks âĸ 2026-06-04T21:45:02Z
Should Vikingâs VK2735 Obesity Program Advancements Require Action From Viking Therapeutics (VKTX) Investors?
Simply Wall St. âĸ 2026-06-03T18:13:08Z
Bull vs. Bear: The Quick Take on Viking Therapeutics Stock
Motley Fool âĸ 2026-06-03T11:09:00Z
VKTX Eyes Worst Week Since November As Trial Data Looms â Wall Street Still Sees 200% Upside
Stocktwits âĸ 2026-06-02T23:43:15Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $393,342,000 | $150,921,000 | $100,827,000 | $70,355,000 |
| Other Income Expense | $55,000 | $112,000 | - | $-42,000 |
| Net Non Operating Interest Income Expense | $33,648,000 | $40,846,000 | $14,932,000 | $1,530,000 |
| Total Other Finance Cost | $56,000 | $94,000 | $88,000 | $59,000 |
| Operating Expense | $393,342,000 | $150,921,000 | $100,827,000 | $70,355,000 |
| General And Administrative Expense | $48,387,000 | $49,277,000 | $37,021,000 | $16,121,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-359,639,000 | $-109,963,000 | $-85,895,000 | $-68,867,000 |
| Net Interest Income | $33,648,000 | $40,846,000 | $14,932,000 | $1,530,000 |
| Interest Income | $33,704,000 | $40,940,000 | $15,020,000 | $1,589,000 |
| Normalized Income | $-359,694,000 | $-110,075,000 | $-85,895,000 | $-68,825,000 |
| Net Income From Continuing And Discontinued Operation | $-359,639,000 | $-109,963,000 | $-85,895,000 | $-68,867,000 |
| Total Operating Income As Reported | $-393,342,000 | $-150,921,000 | $-100,827,000 | $-70,355,000 |
| Net Income Common Stockholders | $-359,639,000 | $-109,963,000 | $-85,895,000 | $-68,867,000 |
| Net Income | $-359,639,000 | $-109,963,000 | $-85,895,000 | $-68,867,000 |
| Net Income Including Noncontrolling Interests | $-359,639,000 | $-109,963,000 | $-85,895,000 | $-68,867,000 |
| Net Income Continuous Operations | $-359,639,000 | $-109,963,000 | $-85,895,000 | $-68,867,000 |
| Pretax Income | $-359,639,000 | $-109,963,000 | $-85,895,000 | $-68,867,000 |
| Interest Income Non Operating | $33,704,000 | $40,940,000 | $15,020,000 | $1,589,000 |
| Operating Income | $-393,342,000 | $-150,921,000 | $-100,827,000 | $-70,355,000 |
| Per Share | ||||
| Diluted EPS | $-3.19 | $-1.01 | $-0.91 | $-0.90 |
| Basic EPS | $-3.19 | $-1.01 | $-0.91 | $-0.90 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-392,966,000 | $-150,687,000 | $-100,535,000 | $-70,022,000 |
| Total Unusual Items | $55,000 | $112,000 | - | $-42,000 |
| Total Unusual Items Excluding Goodwill | $55,000 | $112,000 | - | $-42,000 |
| Reconciled Depreciation | $431,000 | $346,000 | $292,000 | $291,000 |
| EBITDA (Bullshit earnings) | $-392,911,000 | $-150,575,000 | $-100,535,000 | $-70,064,000 |
| EBIT | $-393,342,000 | $-150,921,000 | $-100,827,000 | $-70,355,000 |
| Diluted Average Shares | $112,667,000 | $109,037,000 | $94,347,000 | $76,834,000 |
| Basic Average Shares | $112,667,000 | $109,037,000 | $94,347,000 | $76,834,000 |
| Diluted NI Availto Com Stockholders | $-359,639,000 | $-109,963,000 | $-85,895,000 | $-68,867,000 |
| Gain On Sale Of Security | $55,000 | $112,000 | - | $-42,000 |
| Research And Development | $344,955,000 | $101,644,000 | $63,806,000 | $54,234,000 |
| Selling General And Administration | $48,387,000 | $49,277,000 | $37,021,000 | $16,121,000 |
| Other Gand A | $48,387,000 | $49,277,000 | $37,021,000 | $16,121,000 |
Fetched: 2026-06-18
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $639,062,000 | $880,278,000 | $348,419,000 | $145,322,000 |
| Total Assets | $715,729,000 | $908,321,000 | $368,490,000 | $168,529,000 |
| Total Non Current Assets | $131,000 | $1,105,000 | $1,265,000 | $1,489,000 |
| Non Current Prepaid Assets | $46,000 | $46,000 | $33,000 | $33,000 |
| Non Current Deferred Assets | $0 | $56,000 | $106,000 | $38,000 |
| Current Assets | $715,598,000 | $907,216,000 | $367,225,000 | $167,040,000 |
| Other Current Assets | $1,806,000 | $1,128,000 | $2,522,000 | $3,411,000 |
| Prepaid Assets | $8,053,000 | $3,476,000 | $2,624,000 | $8,144,000 |
| Cash Cash Equivalents And Short Term Investments | $705,739,000 | $902,612,000 | $362,079,000 | $155,485,000 |
| Cash And Cash Equivalents | $165,810,000 | $26,676,000 | $55,516,000 | $36,632,000 |
| Debt | ||||
| Total Debt | $137,000 | $1,119,000 | $1,260,000 | $1,564,000 |
| Long Term Debt And Capital Lease Obligation | $0 | $630,000 | $936,000 | $1,260,000 |
| Current Debt And Capital Lease Obligation | $137,000 | $489,000 | $324,000 | $304,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $76,667,000 | $28,043,000 | $20,071,000 | $23,207,000 |
| Total Non Current Liabilities Net Minority Interest | $0 | $630,000 | $936,000 | $1,260,000 |
| Current Liabilities | $76,667,000 | $27,413,000 | $19,135,000 | $21,947,000 |
| Payables And Accrued Expenses | $76,530,000 | $26,924,000 | $18,811,000 | $21,643,000 |
| Payables | $53,251,000 | $9,813,000 | $7,512,000 | $8,529,000 |
| Accounts Payable | $53,251,000 | $9,813,000 | $7,512,000 | $8,529,000 |
| Equity | ||||
| Common Stock Equity | $639,062,000 | $880,278,000 | $348,419,000 | $145,322,000 |
| Total Equity Gross Minority Interest | $639,062,000 | $880,278,000 | $348,419,000 | $145,322,000 |
| Stockholders Equity | $639,062,000 | $880,278,000 | $348,419,000 | $145,322,000 |
| Gains Losses Not Affecting Retained Earnings | $378,000 | $-788,000 | $-389,000 | $-1,102,000 |
| Other Equity Adjustments | $378,000 | $-788,000 | $-389,000 | $-1,102,000 |
| Retained Earnings | $-847,546,000 | $-487,907,000 | $-377,944,000 | $-292,049,000 |
| Other | ||||
| Ordinary Shares Number | $114,793,067 | $111,573,519 | $100,113,770 | $78,257,258 |
| Share Issued | $114,793,067 | $111,573,519 | $102,307,021 | $80,450,509 |
| Tangible Book Value | $639,062,000 | $880,278,000 | $348,419,000 | $145,322,000 |
| Invested Capital | $639,062,000 | $880,278,000 | $348,419,000 | $145,322,000 |
| Working Capital | $638,931,000 | $879,803,000 | $348,090,000 | $145,093,000 |
| Capital Lease Obligations | $137,000 | $1,119,000 | $1,260,000 | $1,564,000 |
| Total Capitalization | $639,062,000 | $880,278,000 | $348,419,000 | $145,322,000 |
| Treasury Stock | $0 | $0 | $6,795,000 | $6,795,000 |
| Additional Paid In Capital | $1,486,229,000 | $1,368,972,000 | $733,546,000 | $445,267,000 |
| Capital Stock | $1,000 | $1,000 | $1,000 | $1,000 |
| Common Stock | $1,000 | $1,000 | $1,000 | $1,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $0 | $630,000 | $936,000 | $1,260,000 |
| Current Capital Lease Obligation | $137,000 | $489,000 | $324,000 | $304,000 |
| Current Accrued Expenses | $23,279,000 | $17,111,000 | $11,299,000 | $13,114,000 |
| Net PPE | $85,000 | $1,003,000 | $1,126,000 | $1,418,000 |
| Gross PPE | $85,000 | $1,003,000 | $1,126,000 | $1,418,000 |
| Buildings And Improvements | $85,000 | $1,003,000 | $1,126,000 | $1,418,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $539,929,000 | $875,936,000 | $306,563,000 | $118,853,000 |
| Treasury Shares Number | - | - | $2,193,251 | $2,193,251 |
Fetched: 2026-06-18
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-278,685,000 | $-87,790,000 | $-73,376,000 | $-48,397,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-278,685,000 | $-87,790,000 | $-73,376,000 | $-48,397,000 |
| Cash Flow From Continuing Operating Activities | $-278,685,000 | $-87,790,000 | $-73,376,000 | $-48,397,000 |
| Operating Gains Losses | $-55,000 | $-112,000 | - | - |
| Investing Activities | ||||
| Investing Cash Flow | $341,388,000 | $-553,366,000 | $-179,086,000 | $54,753,000 |
| Cash Flow From Continuing Investing Activities | $341,388,000 | $-553,366,000 | $-179,086,000 | $54,753,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $0 | $597,094,000 | $269,760,000 | - |
| Financing Cash Flow | $76,439,000 | $612,464,000 | $271,376,000 | $4,163,000 |
| Cash Flow From Continuing Financing Activities | $76,439,000 | $612,464,000 | $271,376,000 | $4,163,000 |
| Net Other Financing Charges | $73,948,000 | $4,557,000 | $-5,152,000 | $10,132,000 |
| Net Common Stock Issuance | $0 | $597,094,000 | $269,760,000 | $-6,817,000 |
| Common Stock Issuance | $0 | $597,094,000 | $269,760,000 | - |
| Repurchase Of Capital Stock | - | $0 | $0 | $-6,817,000 |
| Other | ||||
| End Cash Position | $165,810,000 | $26,676,000 | $55,516,000 | $36,632,000 |
| Beginning Cash Position | $26,676,000 | $55,516,000 | $36,632,000 | $26,371,000 |
| Effect Of Exchange Rate Changes | $-8,000 | $-148,000 | $-30,000 | $-258,000 |
| Changes In Cash | $139,142,000 | $-28,692,000 | $18,914,000 | $10,519,000 |
| Proceeds From Stock Option Exercised | $2,491,000 | $10,813,000 | $6,768,000 | $848,000 |
| Net Investment Purchase And Sale | $341,388,000 | $-553,366,000 | $-179,086,000 | $54,753,000 |
| Sale Of Investment | $759,425,000 | $560,002,000 | $299,217,000 | $176,184,000 |
| Purchase Of Investment | $-418,037,000 | $-1,113,368,000 | $-478,303,000 | $-121,431,000 |
| Change In Working Capital | $48,978,000 | $9,362,000 | $3,548,000 | $10,189,000 |
| Change In Other Current Liabilities | $-505,000 | $-402,000 | $-347,000 | $-189,000 |
| Change In Payables And Accrued Expense | $49,606,000 | $8,119,000 | $-2,834,000 | $12,894,000 |
| Change In Accrued Expense | $6,168,000 | $5,816,000 | $-1,816,000 | $5,809,000 |
| Change In Payable | $43,438,000 | $2,303,000 | $-1,018,000 | $7,085,000 |
| Change In Account Payable | $43,438,000 | $2,303,000 | $-1,018,000 | $7,085,000 |
| Change In Prepaid Assets | $-5,199,000 | $446,000 | $6,408,000 | $-3,130,000 |
| Change In Receivables | $5,076,000 | $1,199,000 | $321,000 | $614,000 |
| Other Non Cash Items | $66,000 | $132,000 | $131,000 | $100,000 |
| Stock Based Compensation | $40,818,000 | $29,712,000 | $16,750,000 | $8,673,000 |
| Amortization Of Securities | $-9,284,000 | $-17,267,000 | $-8,202,000 | $1,217,000 |
| Depreciation Amortization Depletion | $431,000 | $346,000 | $292,000 | $291,000 |
| Depreciation And Amortization | $431,000 | $346,000 | $292,000 | $291,000 |
| Depreciation | $431,000 | $346,000 | $292,000 | $291,000 |
| Gain Loss On Investment Securities | $-55,000 | $-112,000 | - | - |
| Net Income From Continuing Operations | $-359,639,000 | $-109,963,000 | $-85,895,000 | $-68,867,000 |
| Common Stock Payments | - | $0 | $0 | $-6,817,000 |
| Change In Interest Payable | - | - | - | $614,000 |
Fetched: 2026-06-18